SNDX 241220 30.00P (SNDX241220P30000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SNDX241220P30000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 25 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Seeking Alpha13:58 ET
Trending Stocks Today | Molecular Templates Surges 43.71% Post-Market
Moomoo NewsNov 21 16:30 ET
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
Seeking AlphaNov 21 12:14 ET
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Moomoo NewsNov 21 06:31 ET · Ratings
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
Dow JonesNov 19 12:03 ET · Ratings
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Seeking AlphaNov 19 11:06 ET

Comments

Jaguar8

Nov 17 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Trytosaveabit

Nov 15 15:00

News

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· just
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation